Injectable gout drug draws FDA ire

Twenty-three people have died after being injected with colchicine, a gout drug that's FDA-approved only for oral use. Spurred by these reports, the FDA is cracking down on companies that sell the unapproved form.

Colchicine is a highly toxic drug, the FDA says, and overdoses are difficult to avoid when it's given intravenously. The agency gave companies 30 days to stop making injectable colchicine and 180 days to stop shipping it; after that time, FDA permits will be required for manufacturing or shipping.

- read the FDA release
- see this story for more

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.